MX2021007709A - Composiciones farmacéuticas oftálmicas y procedimientos para el tratamiento de las enfermedades de la superficie ocular. - Google Patents

Composiciones farmacéuticas oftálmicas y procedimientos para el tratamiento de las enfermedades de la superficie ocular.

Info

Publication number
MX2021007709A
MX2021007709A MX2021007709A MX2021007709A MX2021007709A MX 2021007709 A MX2021007709 A MX 2021007709A MX 2021007709 A MX2021007709 A MX 2021007709A MX 2021007709 A MX2021007709 A MX 2021007709A MX 2021007709 A MX2021007709 A MX 2021007709A
Authority
MX
Mexico
Prior art keywords
methods
pharmaceutical compositions
ocular surface
surface disease
treating ocular
Prior art date
Application number
MX2021007709A
Other languages
English (en)
Spanish (es)
Inventor
Dennis Elias Saadeh
Kamran Hosseini
Richard L Lindstrom
Original Assignee
Surface Ophthalmics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Surface Ophthalmics Inc filed Critical Surface Ophthalmics Inc
Publication of MX2021007709A publication Critical patent/MX2021007709A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A61K38/063—Glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/87—Benzo [c] furans; Hydrogenated benzo [c] furans
    • C07D307/88—Benzo [c] furans; Hydrogenated benzo [c] furans with one oxygen atom directly attached in position 1 or 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
MX2021007709A 2018-12-27 2019-12-04 Composiciones farmacéuticas oftálmicas y procedimientos para el tratamiento de las enfermedades de la superficie ocular. MX2021007709A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862785312P 2018-12-27 2018-12-27
PCT/US2019/064371 WO2020139525A1 (en) 2018-12-27 2019-12-04 Ophthalmic pharmaceutical compositions and methods for treating ocular surface disease

Publications (1)

Publication Number Publication Date
MX2021007709A true MX2021007709A (es) 2021-12-15

Family

ID=71127864

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021007709A MX2021007709A (es) 2018-12-27 2019-12-04 Composiciones farmacéuticas oftálmicas y procedimientos para el tratamiento de las enfermedades de la superficie ocular.

Country Status (12)

Country Link
US (1) US12070442B2 (cg-RX-API-DMAC7.html)
EP (1) EP3902525A4 (cg-RX-API-DMAC7.html)
JP (1) JP2022516099A (cg-RX-API-DMAC7.html)
KR (1) KR20210141448A (cg-RX-API-DMAC7.html)
CN (1) CN113473970A (cg-RX-API-DMAC7.html)
AU (1) AU2019417161B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021012492A2 (cg-RX-API-DMAC7.html)
CA (1) CA3124945A1 (cg-RX-API-DMAC7.html)
IL (1) IL284344A (cg-RX-API-DMAC7.html)
MX (1) MX2021007709A (cg-RX-API-DMAC7.html)
SG (1) SG11202106967QA (cg-RX-API-DMAC7.html)
WO (1) WO2020139525A1 (cg-RX-API-DMAC7.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3548091T (pt) 2016-11-29 2022-01-21 Oculis SA Preparação de complexos sólidos de ciclodextrina para administração oftálmica de ingrediente farmacêutico ativo
US11766421B2 (en) * 2017-09-25 2023-09-26 Surface Ophthalmics, Inc. Ophthalmic pharmaceutical compositions and methods for treating ocular surface disease
WO2022076398A1 (en) * 2020-10-07 2022-04-14 Surface Ophthalmics, Inc. Pharmaceutical kits and their use for treating dry eye disease
JP2022516099A (ja) 2018-12-27 2022-02-24 サーフィス オフサルミクス,インコーポレイテッド 眼科用医薬組成物及び癌表面疾患の処置方法
WO2021001366A1 (en) 2019-07-01 2021-01-07 Oculis SA Method for stabilizing the ph of an aqueous composition comprising a drug
CN117979951A (zh) 2021-05-10 2024-05-03 瑟菲斯眼科股份有限公司 一种用于缓解眼部疼痛的硫酸软骨素的用途
US12440510B2 (en) 2021-05-10 2025-10-14 Surface Ophthalmics, Inc. Use of chondroitin sulfate for relieving ocular pain
WO2023141334A2 (en) * 2022-01-24 2023-07-27 Surface Ophthalmics, Inc. Pharmaceutical compositions of mycophenolic acid and/or betamethasone for the treatment of ocular disorders
IL320428A (en) 2022-11-04 2025-06-01 Qlaris Bio Inc Topical ophthalmic administration of cromolyns
EP4616843A1 (en) * 2024-03-13 2025-09-17 Iakov Mirkin Pharmaceutical composition for use in the treatment of ulcerative colitis and in the treatment of interstitial cystitis/bladder pain syndrome

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2503563A1 (fr) 1981-04-09 1982-10-15 Pos Lab Composition pour collyre a base de sulfate de chondroitine a
US4863907A (en) 1984-06-29 1989-09-05 Seikagaku Kogyo Co., Ltd. Crosslinked glycosaminoglycans and their use
US4696917A (en) 1985-08-01 1987-09-29 Lindstrom Richard L Irrigation solution
CA2041828A1 (en) 1990-03-05 1992-11-04 Richard L. Lindstrom Viscoelastic solution
ES2154262T3 (es) 1991-04-26 2001-04-01 Fujisawa Pharmaceutical Co Uso de compuestos macrolidos para enfermedades oculares.
US5518732A (en) 1995-02-14 1996-05-21 Chiron Vision, Inc. Bio-erodible ophthalmic shield
US7063857B1 (en) 1999-04-30 2006-06-20 Sucampo Ag Use of macrolide compounds for the treatment of dry eye
CZ20013769A3 (cs) 1999-04-30 2002-03-13 Sucampo Ag Činidlo pro léčbu suchého oka
US6489335B2 (en) 2000-02-18 2002-12-03 Gholam A. Peyman Treatment of ocular disease
PT1142566E (pt) * 2000-04-07 2004-02-27 Medidom Lab Formulacao oftalmica topica na forma de uma solucao aquosa e uso de uma ciclosporina em associacao com acido hialuronico ou um de seus sais e com polisorbato 80
CN1127955C (zh) 2000-07-07 2003-11-19 中山医科大学中山眼科中心 一种眼前段及眼表免疫相关性疾病治疗药物
DE10045343B4 (de) 2000-09-14 2005-05-12 Neuhann, Tobias, Dr.med. Verwendung einer wässrigen Lösung oder Suspension zum Heilen des Hornhautepithels
US6878694B2 (en) 2000-12-20 2005-04-12 Alcon, Inc. Ophthalmic irrigating solution adapted for use in lasik surgery
US7083803B2 (en) 2003-09-19 2006-08-01 Advanced Ocular Systems Limited Ocular solutions
US7087237B2 (en) * 2003-09-19 2006-08-08 Advanced Ocular Systems Limited Ocular solutions
EP1706095B1 (en) 2004-01-20 2008-12-24 Allergan, Inc. Compositions for localized therapy of the eye, comprising preferably triamcinolone acetonide and hyaluronic acid
GB0404693D0 (en) 2004-03-02 2004-04-07 Univ London Pharmaceutical preparations for the treatment of ocular surface and other disorders
US7820639B2 (en) 2004-10-01 2010-10-26 Lindstrom Richard L Ophthalmic compositions including lubricant, deturgescent agent, and glycosaminoglycan and methods of using the same
CA2584427A1 (en) 2004-11-23 2006-06-01 Alcon, Inc. Triple natural polymer viscoelastic composition
US20060148686A1 (en) * 2004-12-30 2006-07-06 Bausch & Lomb Incorporated Ophthalmic compositions comprising steroid and cyclosporine for dry eye therapy
US20070082841A1 (en) * 2005-09-27 2007-04-12 Aciont, Inc. Ocular administration of immunosuppressive agents
DE102005055275A1 (de) 2005-11-17 2007-05-24 Ursapharm Arzneimittel Gmbh & Co. Kg Phosphatfreie pharmazeutische Zusammensetzung sowie deren Verwendung
KR101478164B1 (ko) 2006-02-09 2014-12-31 산텐 세이야꾸 가부시키가이샤 안정한 제제와 그 제조 및 사용 방법
US20070259021A1 (en) 2006-05-01 2007-11-08 Friedlaender Mitchell H Compositions, Methods, and Kits for Treating Dry Eye
US20080242646A1 (en) 2007-03-26 2008-10-02 Lessem Jan N Split dose corticosteroid therapy
JP5202986B2 (ja) 2007-09-14 2013-06-05 ロート製薬株式会社 コンタクトレンズ装着液
US9034843B2 (en) 2007-09-14 2015-05-19 Rohto Pharmaceutical Co., Ltd. Ophthalmic composition
EP2229174A1 (en) 2007-12-04 2010-09-22 Novagali Pharma S.A. Compositions comprising corticosteroid prodrug such as dexamethasone palmitate for the treatment of eye disorders
JP2011527339A (ja) * 2008-07-09 2011-10-27 アスプレバ インターナショナル リミテッド 眼障害を処置するためのミコフェノール酸ナトリウムのpH特異的な溶液
US10980818B2 (en) 2009-03-06 2021-04-20 Sun Pharma Global Fze Methods for treating ocular inflammatory diseases
US10201548B2 (en) 2009-03-06 2019-02-12 Sun Pharma Global Fze Methods for treating ocular inflammatory diseases
JP5595206B2 (ja) 2009-09-30 2014-09-24 ロート製薬株式会社 眼科用液体組成物
EP2308468A1 (en) 2009-10-08 2011-04-13 Novaliq GmbH Novel pharmaceutical composition comprising a macrolide immunosuppressant drug
WO2011059819A2 (en) 2009-10-29 2011-05-19 Colorado State University Research Foundation Polymeric materials including a glycosaminoglycan networked with a polyolefin-containing polymer
FR2962044B1 (fr) 2010-04-21 2013-02-22 Horus Pharma Emulsion lacrymimetique
US9233123B1 (en) 2010-12-07 2016-01-12 Richard L. Lindstrom Use of ophthalmic compositions including lubricant, deturgescent agent, and glycosaminoglycan
EP2695621B1 (en) 2011-04-08 2020-08-12 Nanotheta Co, Ltd. Pharmaceutical preparation
AU2013216861B2 (en) * 2012-02-10 2017-05-18 Tlc Biopharmaceuticals, Inc Pharmaceutical compositions to reduce complications of ocular steroid
WO2013126602A1 (en) 2012-02-21 2013-08-29 Massachusetts Eye & Ear Infirmary Inflammatory eye disorders
ITPD20120098A1 (it) 2012-03-30 2013-10-01 Fidia Farmaceutici "nuove formulazioni faramaceutiche contenenti condroitin solfato e derivati dell'acido ialuronico"
ITMI20120896A1 (it) 2012-05-23 2013-11-24 Bongulielmi Reto Condroitina per uso in medicina
JP6452283B2 (ja) 2012-11-06 2019-01-16 ロート製薬株式会社 眼の異物感改善剤
AU2013342275B2 (en) * 2012-11-08 2017-11-09 Clearside Biomedical, Inc. Methods and devices for the treatment of ocular diseases in human subjects
JP6403062B2 (ja) 2012-12-21 2018-10-10 国立大学法人徳島大学 組織修復活性組成物及びその利用
US10098962B2 (en) 2013-07-10 2018-10-16 Seikagaku Corporation Glycosaminoglycan derivative and method for producing same
US20150100348A1 (en) 2013-10-08 2015-04-09 Ims Health Incorporated Secure Method for Health Record Transmission to Emergency Service Personnel
EP2979689A1 (en) 2014-07-29 2016-02-03 Sygene Technologies Composition for an eye drop and delivery system therefor
JP2016050181A (ja) * 2014-08-29 2016-04-11 大日本住友製薬株式会社 血管炎治療剤
WO2016114397A1 (ja) 2015-01-16 2016-07-21 生化学工業株式会社 コンドロイチン硫酸架橋体、並びにこれを含有する組成物、及び眼疾患処置剤
TWI773641B (zh) 2015-05-08 2022-08-11 日商活效製藥股份有限公司 含有糖皮質類固醇(glucocorticoids)之奈米微粒子之水性懸浮液劑
US9789080B2 (en) * 2015-09-04 2017-10-17 Insite Vision Incorporated Ophthalmic formulations of mycophenolic acid
JP6847866B2 (ja) 2016-01-29 2021-03-24 生化学工業株式会社 コンドロイチン硫酸及びヒアルロン酸を含有する安定化された水性組成物
JP7288289B2 (ja) 2016-11-11 2023-06-07 ロート製薬株式会社 水性眼科組成物
AU2017372976B2 (en) 2016-12-11 2023-12-07 Seanergy Dermatology Ltd. Compositions comprising sulfated polysaccharides
WO2018114557A1 (en) 2016-12-22 2018-06-28 Novaliq Gmbh Compositions comprising tacrolimus for the treatment of intraocular inflammatory eye diseases
US20190008920A1 (en) 2017-05-19 2019-01-10 Ocugen, Inc. Ophthalmic compositions and methods of use
CN110996904A (zh) * 2017-05-19 2020-04-10 奥古根有限公司 眼用组合物及使用方法
US11766421B2 (en) 2017-09-25 2023-09-26 Surface Ophthalmics, Inc. Ophthalmic pharmaceutical compositions and methods for treating ocular surface disease
US20220143075A1 (en) 2017-09-25 2022-05-12 Surface Ophthalmics, Inc. Ophthalmic pharmaceutical compositions and methods for treating ocular surface disease
US20230277557A1 (en) 2017-09-25 2023-09-07 Surface Ophthalmics, Inc. Pharmaceutical kits and their use for treating dry eye disease
JP7104553B2 (ja) 2018-03-30 2022-07-21 ロート製薬株式会社 眼科組成物
JP7417365B2 (ja) 2018-05-09 2024-01-18 ロート製薬株式会社 水性眼科組成物
TWI894824B (zh) 2018-05-09 2025-08-21 日商樂敦製藥股份有限公司 眼科組成物
CN113329754A (zh) 2018-11-20 2021-08-31 麻雀制药股份有限公司 用于施用皮质类固醇的方法
JP2022516099A (ja) 2018-12-27 2022-02-24 サーフィス オフサルミクス,インコーポレイテッド 眼科用医薬組成物及び癌表面疾患の処置方法
JP6866412B2 (ja) 2019-02-28 2021-04-28 株式会社伊勢半 油中水型乳化化粧料
JP7758466B2 (ja) 2019-11-07 2025-10-22 ロート製薬株式会社 眼科組成物
WO2021162529A1 (ko) 2020-02-14 2021-08-19 연세대학교 산학협력단 페놀 유도체가 수식된 콘드로이틴 설페이트 하이드로젤 및 이의 용도
JP2022157707A (ja) 2021-03-31 2022-10-14 ロート製薬株式会社 眼科組成物
US12359542B2 (en) 2021-05-12 2025-07-15 Schlumberger Technology Corporation Autonomous inflow control device system and method
WO2023141334A2 (en) 2022-01-24 2023-07-27 Surface Ophthalmics, Inc. Pharmaceutical compositions of mycophenolic acid and/or betamethasone for the treatment of ocular disorders

Also Published As

Publication number Publication date
KR20210141448A (ko) 2021-11-23
BR112021012492A2 (pt) 2021-09-08
CN113473970A (zh) 2021-10-01
WO2020139525A1 (en) 2020-07-02
EP3902525A1 (en) 2021-11-03
AU2019417161A1 (en) 2021-07-15
US20220071945A1 (en) 2022-03-10
JP2022516099A (ja) 2022-02-24
SG11202106967QA (en) 2021-07-29
IL284344A (en) 2021-08-31
EP3902525A4 (en) 2022-09-28
CA3124945A1 (en) 2020-07-02
AU2019417161B2 (en) 2023-06-15
US12070442B2 (en) 2024-08-27

Similar Documents

Publication Publication Date Title
AU2018338608A1 (en) Methods, compositions, and implantable elements comprising active cells
PH12022550167A1 (en) High concentration anti-c5 formulations
WO2016196776A3 (en) Inhibitors of bruton's tyrosine kinase
BR112018003985A2 (pt) macrociclos peptidomiméticos e usos dos mesmos
PH12021550621A1 (en) Ophthalmic compositions for treatment of ocular surface damage and symptoms of dryness
HK1250940A1 (zh) 用於预防上皮细胞的增殖和上皮-间充质转换的组合物和方法
EP4599848A3 (en) Methods and compositions related to combined treatment with anti-inflammatories and synthetic nanocarriers comprising an immunosuppressant
WO2019209962A8 (en) Compounds and uses thereof
MY196448A (en) Anti-Htra1 Antibodies and Methods of use Thereof
PH12019500208A1 (en) Spiro-lactam nmda receptor modulators and methods of using same
EP4454704A3 (en) Methods for increasing sepiapterin plasma exposure
WO2019209948A8 (en) Compounds and uses thereof
PH12021550605A1 (en) Farnesoid x receptor agonists and uses thereof
MX2021004755A (es) Uso de plasma y fracciones de plasma para mejorar el dolor, la cicatrizacion de heridas y la recuperacion posoperatoria.
MX2017015879A (es) Composiciones de hidroxipropil beta-ciclodextrina y metodos.
MX2019013151A (es) Composiciones y metodos para expresar otoferlina.
EA033345B1 (ru) ТРИЦИКЛИЧЕСКИЕ СУЛЬФОНЫ В КАЧЕСТВЕ МОДУЛЯТОРОВ RORγ
PH12019501945B1 (en) Composition and method for preventing or delaying onset of myopia comprising atropine
EP4410312A3 (en) Topical cyclosporine-containing formulations and uses thereof
MX2022000712A (es) Moduladores de nlrp3.
MX2016015211A (es) Formulaciones topicas y usos de las mismas.
WO2016191458A3 (en) Pharmaceutical compositions affecting mitochondrial redox state and methods of treatment
AU2017248276A1 (en) Methods of treating ocular conditions
EP4417259A3 (en) Compositions and methods for prevention and treatment of corneal haze and scarring
MX2018005226A (es) Formulaciones de anticuerpo anti-factor d.